Structure Therapeutics (GPCR) Change in Accured Expenses (2022 - 2026)
Quarterly Change in Accured Expenses rose 86.51% to -$134000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $22.4 million through Mar 2026, up 129.28% year-over-year, with the annual reading at $21.5 million for FY2025, 178.79% up from the prior year.
Structure Therapeutics' Change in Accured Expenses history spans 5 years, with the latest figure at -$134000.0 for Q1 2026.
- Change in Accured Expenses came in at -$134000.0 for Q1 2026, down from $15.0 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $15.0 million in Q4 2025 to a low of -$3.0 million in Q1 2024.
- The 5-year median for Change in Accured Expenses is $2.5 million (2022), against an average of $2.5 million.
- Year-over-year, Change in Accured Expenses skyrocketed 5526.79% in 2023 and then tumbled 446.67% in 2024.
- Structure Therapeutics' Change in Accured Expenses stood at $56000.0 in 2022, then surged by 5526.79% to $3.2 million in 2023, then decreased by 4.03% to $3.0 million in 2024, then surged by 396.76% to $15.0 million in 2025, then tumbled by 100.89% to -$134000.0 in 2026.
- Per Business Quant, the three most recent readings for GPCR's Change in Accured Expenses are -$134000.0 (Q1 2026), $15.0 million (Q4 2025), and $3.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 107.70 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Structure Therapeutics | 8.43 Bn | 8.43 Bn | - | -134,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -134,000.00 |
| Mar 31, 2026 | -134,000.00 |
| Dec 31, 2025 | 15.02 Mn |
| Dec 31, 2025 | 15.02 Mn |
| Sep 30, 2025 | 3.88 Mn |
| Sep 30, 2025 | 3.88 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Mar 31, 2025 | -993,000.00 |
| Mar 31, 2025 | -993,000.00 |
| Dec 31, 2024 | 3.02 Mn |
| Dec 31, 2024 | 3.02 Mn |
| Sep 30, 2024 | 5.55 Mn |
| Sep 30, 2024 | 5.55 Mn |
| Jun 30, 2024 | 2.18 Mn |
| Jun 30, 2024 | 2.18 Mn |
| Mar 31, 2024 | -3.03 Mn |
| Mar 31, 2024 | -3.03 Mn |
| Dec 31, 2023 | 3.15 Mn |
| Dec 31, 2023 | 3.15 Mn |
| Sep 30, 2023 | 6.09 Mn |
| Sep 30, 2023 | 6.09 Mn |
| Jun 30, 2023 | 3.48 Mn |
| Jun 30, 2023 | 3.48 Mn |
| Mar 31, 2023 | -555,000.00 |
| Mar 31, 2023 | -555,000.00 |
| Dec 31, 2022 | 56,000.00 |
| Dec 31, 2022 | 56,000.00 |
| Sep 30, 2022 | -1.54 Mn |
| Sep 30, 2022 | -1.54 Mn |
| Jun 30, 2022 | 2.49 Mn |
| Jun 30, 2022 | 2.49 Mn |
| Mar 31, 2022 | 536,000.00 |
| Mar 31, 2022 | 536,000.00 |